Regeneron Pharmaceuticals Balance Sheet

Financials in millions USD. Fiscal year is January - December.

Millions USD. Fiscal year is Jan - Dec.

Fiscal Year	FY 2025	FY 2024	FY 2023	FY 2022	FY 2021
Period Ending	Dec '25 Dec 31, 2025	Dec '24 Dec 31, 2024	Dec '23 Dec 31, 2023	Dec '22 Dec 31, 2022	Dec '21 Dec 31, 2021
Cash & Equivalents	18,866	2,488	2,730	3,106	2,886
Short-Term Investments	-	6,524	8,115	4,636	2,809
Cash & Short-Term Investments	18,866	9,013	10,845	7,742	5,695
Cash Growth	109.33%	-16.90%	40.07%	35.96%	58.76%
Accounts Receivable	5,741	5,844	5,299	5,023	5,059
Other Receivables	-	367.8	368.5	305.6	977.5
Receivables	5,741	6,212	5,667	5,329	6,037
Inventory	3,201	3,087	2,581	2,402	1,951
Prepaid Expenses	-	348.4	386.6	411.2	332.4
Restricted Cash	-	0.8	-	-	-
Total Current Assets	27,808	18,661	19,479	15,884	14,015
Property, Plant & Equipment	5,120	4,817	4,224	3,834	3,482
Long-Term Investments	-	9,060	5,471	6,640	6,878
Other Intangible Assets	1,257	1,149	1,039	915.5	6.7
Long-Term Deferred Tax Assets	4,077	3,314	2,575	1,724	876.9
Other Long-Term Assets	2,296	758.8	291.8	216.9	176.1
Total Assets	40,559	37,759	33,080	29,215	25,435
Accounts Payable	5,834	789.5	606.6	589.2	564
Accrued Expenses	-	2,497	2,339	2,054	1,593
Current Portion of Leases	-	30.3	19	12.4	719.7
Current Income Taxes Payable	-	-	-	-	326.3
Current Unearned Revenue	-	627.7	458.9	485.3	442
Other Current Liabilities	-	-	-	-	287.4
Total Current Liabilities	5,834	3,944	3,423	3,141	3,933
Long-Term Debt	1,986	1,984	1,983	1,981	1,980
Long-Term Leases	720	924.1	788.7	775.8	-
Long-Term Unearned Revenue	761.7	185.7	126.7	69.8	73.3
Other Long-Term Liabilities	-	1,367	785.4	582.2	680.2
Total Liabilities	9,302	8,406	7,107	6,551	6,666
Common Stock	31,257	0.1	0.1	0.1	0.1
Additional Paid-In Capital	-	12,856	11,354	9,949	8,088
Retained Earnings	-	31,673	27,260	23,307	18,968
Treasury Stock	-	-15,167	-12,560	-10,353	-8,261
Comprehensive Income & Other	-	-7.9	-80.9	-238.8	-26.2
Shareholders' Equity	31,257	29,354	25,973	22,664	18,769
Total Liabilities & Equity	40,559	37,759	33,080	29,215	25,435
Total Debt	2,706	2,939	2,791	2,770	2,700
Net Cash (Debt)	16,160	14,974	13,451	11,565	9,833
Net Cash Growth	7.92%	11.32%	16.31%	17.61%	144.18%
Net Cash Per Share	148.80	130.09	118.30	101.89	87.64
Filing Date Shares Outstanding	102.9	106.82	107.46	106.73	106.44
Total Common Shares Outstanding	102.9	107.1	107.12	107	106.57
Working Capital	21,974	14,717	16,056	12,743	10,082
Book Value Per Share	303.76	274.08	242.47	211.81	176.11
Tangible Book Value	30,000	28,205	24,935	21,749	18,762
Tangible Book Value Per Share	291.54	263.35	232.78	203.26	176.05
Land	-	288.2	283.1	264.5	248
Buildings	-	2,573	2,423	2,270	2,089
Machinery	-	2,149	1,940	1,803	1,662
Construction In Progress	-	1,722	1,345	980.5	767.7
Leasehold Improvements	-	154.5	133.9	114.3	113.9

Updated Dec 31, 2025. Source: S&P Global Market Intelligence. Standard template. Financial Sources.